Spencer Feldman

SBRT improved local progression-free survival over RFA in small recurrent HCC, particularly in tumors 2 cm or less.

The addition of nab-paclitaxel to gemcitabine and cisplatin did not improve survival in advanced biliary tract cancer.

Neuropathy, skin rash, and hyperglycemia following enfortumab vedotin treatment were associated with improved PFS in metastatic urothelial carcinoma.

The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision expected by July 10, 2025.

Breyanzi has shown significant efficacy and durable responses in patients with marginal zone lymphoma.

Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events and reduced overall survival.

Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated metastatic colorectal cancer.

A study found no significant HRQOL differences between Erleada-based therapies and ADT plus AAP for advanced castration-sensitive prostate cancer.

Alecensa weight gain is underreported in ALK+ NSCLC trials, highlighting the need for increased awareness and proactive management of this side effect.

A phase 3 trial is evaluating ASP-1929 photoimmunotherapy plus Keytruda in first-line treatment for recurrent head and neck squamous cell carcinoma.

From the reveal of NBA star Dwyane Wade’s cancer surgery to a Bachelorette star on her husband’s cancer diagnosis, here is this week’s top cancer news.

Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission following second-line salvage therapy.

Brukinsa had a lower risk of disease progression or death versus Imbruvica, as well as a more favorable safety profile, in R/R CLL and SLL.

Adults with primary primary appendiceal adenocarcinoma face a higher risk of developing a second primary cancer, including colorectal and prostate cancers.

Missing weekly cisplatin cycles was associated with worse OS in patients with head and neck cancers, particularly for those with p16-negative tumors.

A phase 2a trial of IMM-1-104 plus chemotherapy demonstrated efficacy and tolerability in first- and second-line pancreatic cancer.

PH284 increased feelings of hunger and was safe in patients with cancer cachexia, which results in significant weight loss.

A diet high in omega-3 fatty acids and low in omega-6 fatty acids, taken with fish oil, reduced the Ki-67 index in men with prostate cancer on active surveillance.

Elinzanetant significantly reduced the frequency and severity of hot flashes in women with breast cancer who were undergoing hormone therapy.

Adding hyperthermic intraperitoneal chemotherapy to surgery did not improve progression-free survival in platinum-sensitive recurrent ovarian cancer.

CURE spoke with an expert about the potential positive effects of radiation therapy for patients with hepatocellular carcinoma.

The FDA has granted fast track designation for abenacianine to help surgeons better visualize lung tumors during minimally invasive surgery.

Real-world data supports Opdivo plus Yervoy efficacy for advanced renal cell carcinoma, mirroring clinical trial results.

Stereotactic body radiation therapy combined with Nexavar showed a clinically important improvement in overall survival in locally advanced hepatocellular carcinoma.

Chemotherapy regimen shows potential to improve survival and reduce need for surgery in patients with muscle-invasive bladder cancer.

Chimerix submitted a new drug application to the FDA seeking accelerated approval for dordaviprone to treat patients with recurrent H3 K27M-mutant diffuse glioma.

In patients with triple-negative breast cancer, ctDNA was most commonly identified within six months after treatment, reflecting the disease’s typical pattern of early recurrence.

A combination of Imbruvica and venetoclax showed significantly prolonged progression-free survival in patients with untreated CLL, an expert explained.

In certain patients with ESR1-mutant breast cancer, time to next treatment was slightly higher with Orserdu versus PFS in a phase 3 trial.

Maggie Bushway reflected on her memoir “Pearls: A Memoir on Childhood Cancer and Hope,” and her journey of healing and resilience after brain cancer.